The “Parkinsons Disease Drugs Market” research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. Parkinsons Disease Drugs market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Parkinsons Disease Drugs market report also offers market competitors that includes detailed company profiles along with company product specifications.
Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14099025
In Parkinsons Disease Drugs Market Report, Following Companies Are Covered:
Parkinsons Disease Drugs Market 2019 report will help the industry aspirants in arranging their strategies. The measurements offered in this report will be an exact and helpful manual to shape the business development. Additionally, will Provide historical data along with a future forecast and detailed analysis and also expected opportunities.
Scope of the Report:
Reasons for Buying Parkinsons Disease Drugs Market Report:
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a five-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14099025
Key Market Trends:
COMT (Catechol-O-Methyltransferase) Inhibitors are expected to Register Robust growth
Carbidopa-levodopa Therapy is the most effective medication for alleviating the motor symptoms of PD. However, it has been observed that this medication is not as effective as intended. Therefore, it is imperative that co-therapeutic agents, such as COMT (catechol-O-methyltransferase) inhibitors, are used along with carbidopa-levodopa therapy. The two most common COMT inhibitors, used in the treatment of Parkinsons disease, are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of tablets. In addition, these medications are routinely prescribed in conjunction with carbidopa-levodopa therapy.
The United States Represents the Largest Market for Parkinson’s Disease Therapeutics
According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinsons disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson’s disease (PD) will continue to grow, and this is expected to double by 2040. The sheer number of Parkinsons disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Furthermore, the high cost of Parkinson’s disease therapeutics in the United States also leads to significant market size in terms of revenue. The average cost of Parkinsons medication is approximately USD 2,500 per year and Parkinsons-related surgery can cost up to USD 100,000 per patient.
The Research Document Will Answer Following Questions Such as:
- What are the cutting-edge technologies responsible for driving the growth of the market?
- What are the main applications of the market? What are the growth prospects to the market applications into the market?
- At what stage of development are the key market products?
- What are the shortcomings that has to face to become commercially viable? Is their growth and commercialization dependent on cost declines or technological/application breakthroughs?
- What is the outlook for the industry?
- What difference does performance characteristics of Parkinsons Disease Drugs create from those of established entities?
Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/14099025
Detailed TOC of Parkinsons Disease Drugs Market Report 2019-2024:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Recent Drug Approvals
4.2.3 Growing Awareness
4.3 Market Restraints
4.3.1 Generic Competition to Key Therapies
4.3.2 High Cost of Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Mechanism of Action
5.1.1 Dopamine Agonists
5.1.3 MAO-B inhibitors
5.1.6 COMT Inhibitors
5.1.7 Other Mechanisms of Action
5.2.1 North America
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.2.4 Middle East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East & Africa
5.2.5 South America
220.127.116.11 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 Impax Laboratories Inc.
6.1.3 AbbVie Inc.
6.1.4 Mylan NV
6.1.5 Boehringer Ingelheim
6.1.6 GlaxoSmithKline plc
6.1.7 M Somerset Pharmaceuticals Inc.
6.1.8 Teva Pharmaceuticals Industries Ltd
6.1.9 Pfizer Inc.
6.1.10 Novartis AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: